These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35915658)

  • 1. BCHE as a Prognostic Biomarker in Endometrial Cancer and Its Correlation with Immunity.
    Liu J; Tian T; Liu X; Cui Z
    J Immunol Res; 2022; 2022():6051092. PubMed ID: 35915658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
    Lai J; Xu T; Yang H
    BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
    Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
    Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.
    Ma H; Feng PH; Yu SN; Lu ZH; Yu Q; Chen J
    BMC Cancer; 2022 May; 22(1):543. PubMed ID: 35562682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
    Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
    Front Immunol; 2021; 12():805883. PubMed ID: 35095892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer.
    Wang Y; Zhang J; Zhou Y; Li Z; Lv D; Liu Q
    BMC Cancer; 2021 Nov; 21(1):1203. PubMed ID: 34763648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma.
    Li S; Dong C; Chen J; Gao X; Xie X; Zhang X
    Aging (Albany NY); 2021 Jun; 13(12):16696-16712. PubMed ID: 34158412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment.
    Liu Y; Fu S; Zhang Z; Wang S; Cheng X; Li Z; Ding Y; Sun T; Ma M
    Dis Markers; 2022; 2022():5939021. PubMed ID: 35860689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatic profiling identifies prognosis-related genes in the immune microenvironment of endometrial carcinoma.
    Cheng P; Ma J; Zheng X; Zhou C; Chen X
    Sci Rep; 2021 Jun; 11(1):12608. PubMed ID: 34131259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel risk prediction model of pyroptosis-related genes for the prognosis and immunotherapy response of endometrial cancer.
    Liu ZS; Jing CL
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2259-2278. PubMed ID: 35442481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mining of clinical and prognosis related genes in the tumor microenvironment of endometrial cancer: A field synopsis of observational study.
    Li W; Qin Y; Chen X; Wang X
    Medicine (Baltimore); 2023 Jun; 102(25):e34047. PubMed ID: 37352078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma.
    Tao Y; Liang B
    Pathol Res Pract; 2020 Jun; 216(6):152943. PubMed ID: 32279917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Landscape of PCOS co-expression gene and its role in predicting prognosis and assisting immunotherapy in endometrial cancer.
    Zhang Y; Hu Y; Yu J; Xie X; Jiang F; Wu C
    J Ovarian Res; 2023 Jul; 16(1):129. PubMed ID: 37393293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CKMT1A is a novel potential prognostic biomarker in patients with endometrial cancer.
    Wang Y; Zhao S; Qin Q; Gao X; Zhang X; Zhang M; Jiang Y; Ji X; Zhu H; Zhao X; Li H
    PLoS One; 2022; 17(1):e0262000. PubMed ID: 35077462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer.
    Chen P; Yang Y; Zhang Y; Jiang S; Li X; Wan J
    Aging (Albany NY); 2020 Feb; 12(4):3371-3387. PubMed ID: 32074080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.